#Zentiva #Czech Republic #Prague #Biosimilars #monoclonal antibody

Zentiva's Strategic Move into Biosimilars

Zentiva, a prominent European manufacturer dedicated to providing quality and affordable medications, has made a groundbreaking leap into the realm of biologics by announcing the launch of its first biosimilar monoclonal antibody across the European Union. This pivotal moment, facilitated by approval from the European Medicines Agency (EMA), underscores Zentiva's commitment to improving accessibility to essential treatments for patients throughout Europe.

Setting a New Standard in Healthcare

On December 1, 2025, the company recognized its mission's expansion, as noted by CEO Steffen Saltofte, who emphasized the company's determination to deliver high-quality medicines at accessible prices. "Today's official unveiling is a key moment for Zentiva," he stated. "We have taken significant steps into the area of biologics, extending our portfolio beyond traditional generic medications. Our aim is to provide better and more affordable healthcare solutions to patients across Europe. This expansion not only enhances our offerings but also positions Zentiva for sustainable growth in one of the most dynamic sectors of the pharmaceutical industry."

The Role of Biosimilars in Modern Medicine

Biosimilars are biologic medical products highly similar to already approved reference products, demonstrating no significant differences in effectiveness, safety, and quality. The introduction of Zentiva's new biosimilar medicine, specifically designed for the treatment of bone diseases, plays a crucial role in ensuring the sustainability of healthcare systems while broadening patients' access to modern therapies. As healthcare expenses rise across Europe, the demand for biosimilars continues to grow, leading to innovative solutions that align with global healthcare strategies.

A Step Towards Future Growth

Zentiva's new monoclonal antibody will gradually become available in European markets starting from December. This launch is part of a broader strategic development plan aimed at diversifying Zentiva’s portfolio beyond traditional generics. The rising demand for biological therapies reflects an industry shift that is pivotal for ensuring comprehensive patient care. As biologics account for a growing share of healthcare spending, biosimilars are set to play a significant role in improving the cost-effectiveness of therapies, thus benefiting patients and healthcare systems alike.

About Zentiva

Zentiva is dedicated to enhancing the health and comfort of all generations by focusing on the development, production, and delivery of high-quality pharmaceutical products for over 100 million residents across more than 30 countries in Europe and beyond. The company ensures the safety and reliability of its supply chain through four wholly-owned manufacturing facilities and a robust network of external manufacturing partners. With more than 5,000 dedicated talents, Zentiva commits to ensuring quality and access for those who rely on its medicines daily. As a private firm, Zentiva looks to the future with an ambitious sustainable growth plan, ready to face upcoming challenges in healthcare delivery. To learn more, visit www.zentiva.com.